Related Experiment Video
Updated: Jan 7, 2026
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve
Insights
Pemafibrate, a PPARα activator, reduced aortic stenosis progression and valve calcification in mice by modulating macrophage-valve interstitial cell crosstalk, independent of lipid changes. Further clinical trials are warranted.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Translational Medicine
Background:
- Calcific aortic valve disease (CAVD) leads to aortic stenosis (AS), causing significant cardiovascular dysfunction.
- Current treatments for severe AS are limited to valve replacement, highlighting the need for novel pharmacotherapies.
- Pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARα) activator, was investigated as a potential therapeutic for CAVD and AS.
Purpose of the Study:
- To evaluate the efficacy of pemafibrate in treating experimental calcific aortic valve disease and aortic stenosis.
- To elucidate the mechanisms underlying pemafibrate's action, particularly its effects on inflammation and cellular crosstalk.
Main Methods:
- An aortic valve wire injury (AVWI) model in Ldlr-/- mice was used to study AS progression.
- Pemafibrate was administered to mice, and its effects on valvular calcification, inflammation, and macrophage infiltration were assessed.
- In vitro studies involved primary human valvular interstitial cells (VICs) and macrophages to investigate inflammation-mediated calcification and cellular crosstalk.
- Proteomic analyses were performed on patient serum from the PROMINENT trial and human calcified aortic valve tissue.
Main Results:
- Pemafibrate treatment significantly reduced valvular calcification by 39% and improved aortic valve function in the mouse model.
- These benefits were observed independently of changes in plasma triglyceride levels.
- In vitro, pemafibrate suppressed inflammation-driven calcification of VICs by modulating macrophage-derived factors, indicating a key role for macrophage-VIC crosstalk.
- Pemafibrate shifted macrophages towards a less inflammatory phenotype and reduced monocyte activation in patient serum, as evidenced by proteomic analyses.
Conclusions:
- Pemafibrate effectively slows experimental AS progression and valve calcification by modulating macrophage-VIC crosstalk.
- The therapeutic effects of pemafibrate are independent of its lipid-lowering properties.
- These findings support pemafibrate as a promising pharmacological agent for CAVD and warrant further investigation in randomized clinical trials.
Background:
Calcific aortic valve disease (CAVD) compromises valve compliance and cardiac hemodynamics leading to aortic stenosis (AS) and cardiovascular dysfunction. With treatment for severe AS limited to valve replacement and no effective pharmacotherapies, new interventions are urgently needed for patients. This study evaluated pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARα) activator as a novel therapeutic for CAVD and AS.
Methods And Results:
In an aortic valve wire injury (AVWI) model of AS in Ldlr ⁻/⁻ mice, pemafibrate administration (0.2 mg/kg/day) for 15 weeks improved aortic valve function and reduced valvular calcification by 39% (p<0.001), accompanied by reduced leaflet inflammation and CD68⁺ macrophage infiltration. These effects were independent of changes in plasma triglyceride levels. In vitro , pemafibrate suppressed inflammation-mediated calcification of primary human valvular interstitial cells (VICs) by modulating macrophage-derived secreted factors, identifying macrophage-VIC crosstalk as a key disease mechanism. Direct treatment of macrophages with pemafibrate, or exposure to serum from pemafibrate-treated participants in the PROMINENT randomized controlled trial, shifted macrophages toward a less inflammatory and less chemotactic phenotype. Proteomic analyses of patient serum substantiated these findings by reflecting a systemic reduction in inflammatory parameters and monocyte activation. Network integration of the in vitro derived pemafibrate-responsive proteome with human calcified AV tissue proteomes identified aberrant protein translation (GNB2L1, GSPT1) and disrupted bioenergetics (MYDGF, PDIA4) as potential clinically relevant pemafibrate-responsive pathways and effector proteins relevant to AS progression.
Conclusions:
Pemafibrate slows experimental AS progression and valve calcification through modulation of macrophage-VIC crosstalk, independent of lipid lowering. These findings support further evaluation of pemafibrate as a potential pharmacological approach for CAVD and support further testing in randomized clinical trials.
More Related Videos
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
05:47Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
Published on: May 10, 2021
